Jane Street Group LLC Sells 4,380 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Jane Street Group LLC decreased its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,338 shares of the company’s stock after selling 4,380 shares during the period. Jane Street Group LLC owned 0.11% of UroGen Pharma worth $280,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in UroGen Pharma during the 4th quarter worth approximately $1,472,000. Bank of New York Mellon Corp grew its holdings in UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock valued at $1,001,000 after buying an additional 6,430 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in UroGen Pharma during the 4th quarter valued at approximately $126,000. Rhumbline Advisers grew its holdings in shares of UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after purchasing an additional 1,402 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after purchasing an additional 6,207 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Up 3.3%

NASDAQ:URGN opened at $5.00 on Wednesday. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a fifty day simple moving average of $8.99 and a 200-day simple moving average of $10.28. The company has a market cap of $230.54 million, a price-to-earnings ratio of -1.59 and a beta of 0.66. UroGen Pharma Ltd. has a twelve month low of $3.42 and a twelve month high of $20.70.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. Analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Oppenheimer cut their target price on shares of UroGen Pharma from $36.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, May 8th. Scotiabank began coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price target for the company. Finally, HC Wainwright downgraded UroGen Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.14.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.